Tim Buckley elected to Pfizer’s Board of Directors
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Buckley served as Chairman and Chief Executive Officer at Vanguard from 2018 until his retirement in 2024
Wockhardt's yet another novel antibiotic Miqnaf receives favourable recommendation from Subject Expert Committee of CDSCO
HYMPAVZI’s approval is based on Phase 3 study results demonstrating substantial bleed reduction compared to routine prophylaxis
Developed in consultation with clinicians and patients for an enhanced user experience
She reiterated the nation's commitment to eliminating TB as a public health problem by 2030 and ensuring a healthier future for all
MVA-BN approved for use against mpox and smallpox in adolescents 12-17 years of age after expedited review with EMA
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
New indication supported by the MANDARA trial which showed nearly 60% of patients achieved remission and 41% of patients fully stopped taking oral corticosteroids
Wacker Biotech will manufacture the active ingredients of MinervaX’s novel vaccine candidate
Subscribe To Our Newsletter & Stay Updated